Selective Targeting Reactive Oxygen Species for Age-Related Macular Degeneration
Principal Investigator
Zongchao Han, MD, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
July 01, 2019 - June 30, 2022
Grant ID
M2019063
Goals
Age-related macular degeneration (AMD) is an age related problem causing vision loss, mainly affected by the gradual buildup of free radicals, the waste products from our cells. We created a solution to prevent AMD progression which serves as a selective waste collector to pick up any specific free radicals. We look to benefit all AMD patients through our treatment.
Summary
Age-related macular degeneration (AMD) is an age related problem causing vision loss. This disease is most commonly associated with the gradual buildup of free radicals (cellular waste products) within the central region of the retina, known as the macular. By utilizing antioxidant nanoparticles to target and selectively eliminate free radical build up, we have created a potential solution to prevent AMD progression. In this project, we will use our newly developed antioxidant nanoparticle formulations, in both cellular and murine AMD models, to test our hypothesis that the nanoparticle intervention has targeted therapeutics by reducing free radical-induced cell damage, while ensuring minimal side effects on the surrounding normal retinal cells. The overall goal of this project is to combine the established outstanding treatments for AMD, while introducing more effective nano antioxidant treatments. In doing this, we hope to complete the steps necessary to bring a safer and more effective nano antioxidant system into a clinical trial for both dry and wet AMD patients. We look to greatly benefit all AMD patients through our innovative treatment.
Grants
Related Grants
Macular Degeneration Research
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Macular Degeneration Research
Immune Cell Traps in Inflammation and Wet Age-Related Macular Degeneration
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Matthew Rutar, PhD
Immune Cell Traps in Inflammation and Wet Age-Related Macular Degeneration
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Matthew Rutar, PhD